Etude de phase II non contrôlée: traitement de première ligne par sunitinib plus folfiri pour les patients ayant un cancer du rectum avec des métastases synchrones résécables (SUREMETS)
- Conditions
- Patient présentant un cancer du rectum avec métastases synchrones non résécables
- Registration Number
- EUCTR2008-005959-19-FR
- Lead Sponsor
- Fédération Francophone de Cancérologie Digestive
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie sunitinib's synergy with FOLFIRI in rectal cancer metastases?
How does sunitinib plus FOLFIRI compare to standard first-line therapies for resectable synchronous rectal metastases?
Which biomarkers correlate with response to sunitinib-FOLFIRI combination in rectal cancer patients?
What adverse event profiles are associated with sunitinib-FOLFIRI regimens in metastatic rectal cancer?
Are there alternative tyrosine kinase inhibitor combinations for rectal cancer with synchronous metastases?